Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|July 3, 2024

The Benefits of Working with mRNA for Therapeutics

The panelists discuss the advantages of rapid development, versatile applications, and precise dosing, and how they combine to signal a promising future for mRNA therapeutics.

In this Biopharm International Peer Exchange roundtable discussion, participants explored the advantages of mRNA therapeutics. Fouad Atouf, PhD, commented on the rapid development and testing capabilities of mRNA, allowing quick responses to new targets. Constanze Blume, PhD, highlighted the broad range of indications mRNA technology can address, showing its versatility in treating various diseases. Kenneth Chien, MD, PhD, pointed out the precise dosing capabilities of mRNA, which allows for a controlled increase in protein expression and quantitative clinical efficacy. He also discussed the potential for mRNA to facilitate "one-and-done" treatments, such as CRISPR-mediated gene editing, where the transient expression of mRNA is beneficial.

Peter Marks, MD, PhD, added that the familiarity and predictability of the mRNA platform, gained through extensive use during the COVID-19 pandemic, are significant advantages. He also noted the potential for mRNA technology to advance genome editing and the importance of continued learning as mRNA is applied in new therapeutic domains.

Discussion Topics

  • 0:00:08 - Introductions and background of speakers
  • 0:02:42 - Benefits of working with mRNA for therapeutics
  • 0:03:35 - Rapid development and reduced risk of genomic integration with mRNA
  • 0:04:08 - Dosability and one-and-done potential of mRNA therapies
  • 0:05:13 - Familiarity with mRNA platform and versatility for genome editing

Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.
The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.